=Tandem Diabetes Care (TNDM) reported earnings on Fri 27 Oct 2017 (b/o)

Tandem Diabetes Care reports Q3 results, beats on revs; guides FY17 revs in-line 

• Reports Q3 (Sep) loss of $3.09 per share, $0.65 better than the Capital IQ Consensus of ($3.74); GAAP revenues rose 119.7% year/year to $27.0 mln vs the $25.9 mln Capital IQ Consensus.
• Co issues in-line guidance for FY17, sees FY17 GAAP revs of $100-105 mln vs. $101.96 mln Capital IQ Consensus Estimate.
• "Our accomplishments in the third quarter, including the FDA approval and immediate launch of the t:slim X2 Insulin Pump with Dexcom G5 Mobile CGM integration, our demonstration of the market-differentiating Tandem Device Updater, and the introduction of our custom infusion set connector, further strengthen our confidence in Tandem's ability to achieve near and long-term revenue growth...We remain highly focused on driving the business toward profitability by increasing our sales and gross profits, leveraging our early infrastructure investments, and exercising careful cash management."